La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad

Intestinal microbiota (IM) plays a role in the development of obesity and its associated low grade inflammation. Bacterial colonization of the gastrointestinal tract of germ free mice (without microbiota) increases by 60% their fat mass, alters their fasting glucose and insulin levels, triples their...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	MORALES,PAMELA, BRIGNARDELLO,JERUSA, GOTTELAND,MARTÍN
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2010
Materias:	Insulin resistance Obesity Prebiotics
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000800013
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872010000800013
record_format	dspace
spelling	oai:scielo:S0034-988720100008000132010-12-21La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidadMORALES,PAMELABRIGNARDELLO,JERUSAGOTTELAND,MARTÍN Insulin resistance Obesity Prebiotics Intestinal microbiota (IM) plays a role in the development of obesity and its associated low grade inflammation. Bacterial colonization of the gastrointestinal tract of germ free mice (without microbiota) increases by 60% their fat mass, alters their fasting glucose and insulin levels, triples their hepatic triglycerides and induces adipocyte hypertrophy. IM favors fat storage in adipocytes through the inhibition of Fiaf (Fasting Induced Adipocyte Factor), an inhibitor of lipoprotein lipase. Compared with normal weight subjects, the IM from obese exhibits a higher proportion of Firmicutes/Bacteroidetes and is more efficient in extracting energy from foodstuffs. The loss of bodyweight by a hypocaloric diet reverts the proportion of bacteria to that of lean subjects. The intake of a high fat diet also alters the IM, affecting intestinal barrier function and favoring endotoxinemia. These events increase oxidative and pro-inflammatory processes in plasma and peripheral tissues and increment the risk of insulin resistance. Such events are reverted by the administration of pre-biotics which stimulate the growth of Bifdobacterium and Lactobacillus species in the colon, reestablishing the gut homeostasis. Interestingly, products resulting from the fermentation of prebiotics stimulate the differentiation of enteroendocrine cells and the release of glucagon like peptide 1 and peptide YY, that have insulin like and anorexigenic activities, thus contributing to body weight equilibrium.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.138 n.8 20102010-08-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000800013es10.4067/S0034-98872010000800013
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Insulin resistance Obesity Prebiotics
spellingShingle	Insulin resistance Obesity Prebiotics MORALES,PAMELA BRIGNARDELLO,JERUSA GOTTELAND,MARTÍN La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
description	Intestinal microbiota (IM) plays a role in the development of obesity and its associated low grade inflammation. Bacterial colonization of the gastrointestinal tract of germ free mice (without microbiota) increases by 60% their fat mass, alters their fasting glucose and insulin levels, triples their hepatic triglycerides and induces adipocyte hypertrophy. IM favors fat storage in adipocytes through the inhibition of Fiaf (Fasting Induced Adipocyte Factor), an inhibitor of lipoprotein lipase. Compared with normal weight subjects, the IM from obese exhibits a higher proportion of Firmicutes/Bacteroidetes and is more efficient in extracting energy from foodstuffs. The loss of bodyweight by a hypocaloric diet reverts the proportion of bacteria to that of lean subjects. The intake of a high fat diet also alters the IM, affecting intestinal barrier function and favoring endotoxinemia. These events increase oxidative and pro-inflammatory processes in plasma and peripheral tissues and increment the risk of insulin resistance. Such events are reverted by the administration of pre-biotics which stimulate the growth of Bifdobacterium and Lactobacillus species in the colon, reestablishing the gut homeostasis. Interestingly, products resulting from the fermentation of prebiotics stimulate the differentiation of enteroendocrine cells and the release of glucagon like peptide 1 and peptide YY, that have insulin like and anorexigenic activities, thus contributing to body weight equilibrium.
author	MORALES,PAMELA BRIGNARDELLO,JERUSA GOTTELAND,MARTÍN
author_facet	MORALES,PAMELA BRIGNARDELLO,JERUSA GOTTELAND,MARTÍN
author_sort	MORALES,PAMELA
title	La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
title_short	La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
title_full	La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
title_fullStr	La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
title_full_unstemmed	La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad
title_sort	la microbiota intestinal: un nuevo actor en el desarrollo de la obesidad
publisher	Sociedad Médica de Santiago
publishDate	2010
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872010000800013
work_keys_str_mv	AT moralespamela lamicrobiotaintestinalunnuevoactoreneldesarrollodelaobesidad AT brignardellojerusa lamicrobiotaintestinalunnuevoactoreneldesarrollodelaobesidad AT gottelandmartin lamicrobiotaintestinalunnuevoactoreneldesarrollodelaobesidad
_version_	1718436521817669632

La microbiota intestinal: Un nuevo actor en el desarrollo de la obesidad

Ejemplares similares